Coronary Artery Disease and Myocardial Infarction

Heather Currie , Christine Williams ,

Read time: 10m

Edward T Carreras , Donna M Polk ,

FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s
FOURIER-OLE: Long-term Safety of Evolocumab Therapy in Patients with Evident ASCVD

Michelle O'Donoghue,

Watch time: 3m 30s

Sergio Fazio ,

Charles H Hennekens , Danielle Hollar , Arthur S Agatston ,

Marc Sirol ,

Yassir Javaid, , , et al

Watch time: 18m 47s (4 videos)

Abdulah Alrifai , Mohamad Kabach , Jonathan Nieves , et al

Marsha M Neumyer , Bill Bertolino ,

Read time: 11m

Donald E Cutlip ,

Marc P Allard-Ratick , Pratik Sandesara , Arshed A Quyyumi , et al

Media

AHA 23: Preventive Cardiology in 2023

Michael Honigberg,

Watch time: 7m 3s

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 1h 35m 42s (16 videos)
ESC 23 Late-Breaker Discussion: The RECORD MI Registry

Harriette Van Spall, Javed Butler,

Watch time: 9m 37s
ESC 23: The ILUMIEN IV Trial

Ziad A Ali,

Watch time: 4m 12s

Yugo Yamashita,

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)
ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s
ACC.23 Late-Breaker Discussion: The CLEAR-Outcomes Trial

Harriette Van Spall, Steven E Nissen,

Watch time: 16m 12s
View from the Thoraxcenter: What's Hot at ACC.23?

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 22m 4s
Radcliffe & CardioNerds @AHA22: Reduction of Lp(a) With Small Interfering RNA

Gurleen Kaur, Michelle O'Donoghue,

Watch time: 14m 28s
Radcliffe & CardioNerds @AHA22: Reduction of Triglycerides With Pemafibrate

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s
FOURIER-OLE: Implications for Real-World Practice

Robert P Giugliano,

Watch time: 2m 56s

Media

ACC.24: The LIBerate-CVD Trial

Evan A Stein,

Watch time: 7m 18s
ACC.24: Olezarsen for Hypertriglyceridemia and ASCVD

Brian Bergmark,

Watch time: 3m 40s
ACC.24: The ORBITA COSMIC Trial

Rasha Al-Lamee, Michael Foley,

Watch time: 4m 45s

Joost Daemen, Allen Jeremias, Ziad A Ali, et al

Watch time: 55m 46s (1 video)
ACC 2020: Inclisiran Potently and Durably Reduces Ldl-c

Watch time: 13m 43s
ACC 2020: Primary Results of the Voyager PAD Trial

Marc P Bonaca,

Watch time: 7m 9s
View From The Thoraxcenter: What's Hot at ESC 2020

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 15m 53s
ESC 2020: APOC-III Reduction in Cardiovascular Disease

Jean-Claude Tardif,

Watch time: 8m 45s

Yassir Javaid, , , et al

Watch time: 18m 47s (4 videos)
ACC 23: MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients

Christie Ballantyne,

Watch time: 3m 44s

Yugo Yamashita,

ACC 23: Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study

Annapoorna Kini ,

Watch time: 8m 1s

Articles

CTA and MPI—A Comparison in Detecting Significant Coronary Artery Disease

Matthew J Budoff

,

Ambarish Gopal

,

Citation:

US Cardiology 2006;3(2):1–6

Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
  • Views: Views 2291
  • Downloads: Downloads 8